Treatment when standard therapy is difficult

7 evidence topics · 1 source

Objective

Location and study date

No evidence found.

Study design

Eligibility criteria

Reasons standard treatment was difficult

“low KPS, renal dysfunction, and resistance to HD-MTX” (opens the source at this quote in a new tab)

Treatment

Administration for swallowing difficulties

“in suspension through a nasogastric tube” (opens the source at this quote in a new tab)

Study outcomes

Rationale for using clinical response as an observed outcome

Not applicable.

Statistical analysis description

Number of participants (Planned and analyzed)

Description of analysis sets

Not applicable.

Results

Participant disposition

No evidence found.

Baseline characteristics

Measure	Quoted value
Median age, years	“76”
Median KPS	“40”

Efficacy results

Clinical responses in the reported series

“In the present study, five cases of refractory/relapsed PCNSL that are difficult to treat with standard treatment were successfully treated by tirabrutinib.” (opens the source at this quote in a new tab)

Reported response and survival

Measure	Quoted value
Response rate	“100%”
Median survival	“8 months”

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

Adverse reactions

“Three patients developed adverse reactions” (opens the source at this quote in a new tab)

Study limitations

Summary

This five-case series describes selected participants for whom standard treatment was difficult because of low KPS, renal dysfunction, or resistance to high-dose methotrexate. The reported 100% response rate is based on five participants and has no concurrent control group. It should not be treated as a population-level comparative efficacy estimate.